BioTuesdays

Category - Developments

Soricimed Logo
Developments

Soricimed publishes Phase 1 results of SOR-C13

Closely-held Soricimed Biopharma announced publication in the peer-reviewed journal, Investigational New Drugs, The Journal of New Anticancer Agents of its first-in-human Phase 1 study of SOR-C13, a TRPV6 calcium...

February 21, 2017
Arch Therapeutics
Developments

Arch advances 510(k) filing for AC5 hemostat

Arch Therapeutics (OTCQB:ARTH) announced that the 510(k) filing for external use of the AC5 Topical Hemostatic device would be advanced to mid-2017 from the previously announced target of late 2017. “Our...

February 17, 2017
microbix
Developments

Microbix posts 84% jump in Q1 revenue

Microbix Biosystems (TSX:MBX) reported that revenue rose 84% to almost $2-million for the first quarter ended Dec. 31, 2016, from $1.1-million a year earlier. Strong growth in Asian markets and increased sales to the...

February 14, 2017
IntelGenx Logo
Developments

IntelGenx, Tetra in development term sheet

IntelGenx (TSX-V:IGX; OTCQX:IGXT) and Tetra Bio-Pharma (CSE:TBP; OTC: GRPOF) announced the signing of a binding term sheet for the development and commercialization of a drug product containing dronabinol. Under the...

February 9, 2017
RepliCel Life Sciences
Developments

RepliCel receives two patents in Europe

RepliCel Life Sciences (OTCQB:REPCF; TSX-V:RP) announced the granting of two patents in Europe related to its multi-needle dermal injection technologies. The first patent has been validated in a total of 14 national...

February 9, 2017